Cargando…

Anti-Protease Activity Deficient Secretory Leukocyte Protease Inhibitor (SLPI) Exerts Cardioprotective Effect against Myocardial Ischaemia/Reperfusion

Inhibition of proteases shows therapeutic potential. Our previous studies demonstrated the cardioprotection by the Secretory Leukocyte Protease Inhibitor (SLPI) against myocardial ischaemia/reperfusion (I/R) injury. However, it is unclear whether the cardioprotective effect of SLPI seen in our previ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mongkolpathumrat, Podsawee, Kijtawornrat, Anusak, Suwan, Eukote, Unajak, Sasimanas, Panya, Aussara, Pusadee, Tonapha, Kumphune, Sarawut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138276/ https://www.ncbi.nlm.nih.gov/pubmed/35625725 http://dx.doi.org/10.3390/biomedicines10050988

Ejemplares similares

Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2021)

Adeno-associated virus 9 vector-mediated cardiac-selective expression of human secretory leukocyte protease inhibitor attenuates myocardial ischemia/reperfusion injury
por: Mongkolpathumrat, Podsawee, et al.
Publicado: (2022)

Gelatin-coated silicon oxide nanoparticles encapsulated recombinant human secretory leukocyte protease inhibitor (rhSLPI) reduced cardiac cell death against an in vitro simulated ischaemia/reperfusion injury
por: Pikwong, Faprathan, et al.
Publicado: (2023)

Endothelial-Cell-Derived Human Secretory Leukocyte Protease Inhibitor (SLPI) Protects Cardiomyocytes against Ischemia/Reperfusion Injury
por: Kongpol, Kantapich, et al.
Publicado: (2019)

An in vitro endothelial cell protective effect of secretory leukocyte protease inhibitor against simulated ischaemia/reperfusion injury
por: Nernpermpisooth, Nitirut, et al.
Publicado: (2017)

The cardioprotective effects of secretory leukocyte protease inhibitor against myocardial ischemia/reperfusion injury
por: Prompunt, Eakkapote, et al.
Publicado: (2018)

Combination of metformin and p38 MAPK inhibitor, SB203580, reduced myocardial ischemia/reperfusion injury in non-obese type 2 diabetic Goto-Kakizaki rats
por: Sanit, Jantira, et al.
Publicado: (2019)

Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
por: Dickey, Brittney L., et al.
Publicado: (2021)

Production of secretory leucocyte protease inhibitor (SLPI) in human pancreatic beta-cells.
por: Nyström, M, et al.
Publicado: (1999)

Mucosal Progranulin expression is induced by H. pylori, but independent of Secretory Leukocyte Protease Inhibitor (SLPI) expression
por: Wex, Thomas, et al.
Publicado: (2011)

Increased Secretory Leukocyte Protease Inhibitor (SLPI) Production by Highly Metastatic Mouse Breast Cancer Cells
por: Sayers, Kevin T., et al.
Publicado: (2014)

Secretory leukocyte protease inhibitor (SLPI) as a potential target for inhibiting metastasis of triple-negative breast cancers
por: Kozin, Sergey V., et al.
Publicado: (2017)

Secretory Leukocyte Protease Inhibitor (SLPI) Is, like Its Homologue Trappin-2 (Pre-Elafin), a Transglutaminase Substrate
por: Baranger, Kévin, et al.
Publicado: (2011)

Plasma concentrations of secretory leukocyte protease inhibitor (SLPI) differ depending on etiology and severity in community-onset bloodstream infection
por: Lange, Anna, et al.
Publicado: (2019)

Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells
por: Wei, Zhijiang, et al.
Publicado: (2023)

Targeting secretory leukocyte protease inhibitor (SLPI) inhibits colorectal cancer cell growth, migration and invasion via downregulation of AKT
por: Wei, Zhijiang, et al.
Publicado: (2020)

IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release.
por: Westin, U, et al.
Publicado: (1998)

High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence
por: Nugteren, Sandrine, et al.
Publicado: (2022)

Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis
por: Nugteren, Sandrine, et al.
Publicado: (2020)

Secretory Leukocyte Protease Inhibitor (SLPI)—A Novel Predictive Biomarker of Acute Kidney Injury after Cardiac Surgery: A Prospective Observational Study
por: Averdunk, Luisa, et al.
Publicado: (2019)

Combining segments 9 and 10 in DNA and recombinant protein vaccines conferred superior protection against tilapia lake virus in hybrid red tilapia (oreochromis sp.) compared to single segment vaccines
por: Chamtim, Pitakthai, et al.
Publicado: (2022)

Pimobendan prevents cardiac dysfunction, mitigates cardiac mitochondrial dysfunction, and preserves myocyte ultrastructure in a rat model of mitral regurgitation
por: Boonpala, Pakit, et al.
Publicado: (2023)

Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation
por: Tantisuwat, Lalida, et al.
Publicado: (2023)

Differential effects of periopathogens on host protease inhibitors SLPI, elafin, SCCA1, and SCCA2
por: Yin, Lei, et al.
Publicado: (2010)

Homology modeling and virtual screening for antagonists of protease from yellow head virus
por: Unajak, Sasimanas, et al.
Publicado: (2014)

Immunoregulatory role of secretory leukocyte protease inhibitor in allergic asthma
por: Marino, Rafael, et al.
Publicado: (2010)

Effect of Semen on Vaginal Fluid Cytokines and Secretory Leukocyte Protease Inhibitor
por: Agnew, Kathy J., et al.
Publicado: (2008)

Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer
por: Stępień, Tomasz, et al.
Publicado: (2017)

Secretory leukocyte protease inhibitor in punch biopsies from human colonic mucosa.
por: Nyström, M, et al.
Publicado: (2001)

Endogenous secretory leukocyte protease inhibitor inhibits microbial‐induced monocyte activation
por: Nugteren, Sandrine, et al.
Publicado: (2022)

Increased Susceptibility to LPS-induced Endotoxin Shock in Secretory Leukoprotease Inhibitor (SLPI)-deficient Mice
por: Nakamura, Akira, et al.
Publicado: (2003)

How SLPI soothes
por: Van Epps, Heather L.
Publicado: (2005)

Secretory Leukocyte Protease Inhibitor Is an Inducible Antimicrobial Peptide Expressed in Staphylococcus aureus Endophthalmitis
por: Reviglio, Victor E., et al.
Publicado: (2007)

Human papillomavirus infection in head and neck cancer: The role of the secretory leukocyte protease inhibitor
por: HOFFMANN, MARKUS, et al.
Publicado: (2013)

Secretory leukocyte protease inhibitor and risk of heart failure in the Multi-Ethnic Study of Atherosclerosis
por: Sawicki, Konrad Teodor, et al.
Publicado: (2023)

Secretory Leukocyte Protease Inhibitor Protects Against Severe Urinary Tract Infection in Mice
por: Rosen, Anne L., et al.
Publicado: (2023)

Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer
por: Liu, Guiying, et al.
Publicado: (2014)

The Ability of Secretory Leukocyte Protease Inhibitor to Inhibit Apoptosis in Monocytes Is Independent of Its Antiprotease Activity
por: McGarry, Niamh, et al.
Publicado: (2015)

Upregulated Expression of Secretory Leukocyte Protease Inhibitor in Lung by Inhalation of High Concentration of Sulfur Dioxide
por: Liu, Lei, et al.
Publicado: (2018)

Secretory leukocyte protease inhibitor regulates nerve reflex‐mediated skin barrier function in psoriasis
por: Kwiecinska, P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_thpsrd607s79mha5v26a2v5mac